Answer To Peer, Similarities Less 5%, References 2, APA 6

Discuss the process and regulations of Fast Track
Strict processes and regulations are considered are considered by the FDA before the approval of a drug. Moreover, the role of the manufacturing company is very important in that their compliance to ensure that their products and the conditions of their manufacture meet the minimum health requirements. According to Damle et al. (2016), the process and regulations under the provisions of FDA are defined by some aspects of eligibility. For instance, the company in question is required to have many frequent meetings the regulatory body which provides them the opportunity to discuss the development of a drug, and allow the collection of data for the support of approval. The manufacturing company is required to wait for many forms of written communication from the FDA regarding the standards like the design of proposed clinical trials (Damleet al., 2016). It will, therefore, be the role of the company to send the New Drug Application (NDA) to be reviewed by FDA and the eligibility may be confirmed if the criterion utilized is relevant to the stated standards.
Identify which medical conditions warrant the use of “Fast Track” drugs.
FDA has specific principles which must be met by the manufacturing company which occurs in the forms of medical conditions.  On the same note, it is important to note that any newly developed drug is to prevent a condition without current therapy is normally directed at an unmet need. It is therefore expected that the drug in question presents some conditions which may comply with the available health standards (Damle et al., 2016). For example, FDA requires that a drug showing the superior effectiveness and improved effect on the unmet health conditions. Moreover, the regulatory body provides that a drug that is newly developed should be associated with minimum side effects to the users. Furthermore, a drug must address an anticipated or emerging public health need. 
References
Damle, N., Shah, S., Nagraj, P., Tabrizi, P., Rodriguez, G., & Bhambri, R. (2016). FDA’s Expedited Programs and Their Impact on the Availability of New Therapies. Therapeutic Innovation & Regulatory Science, 51(1), 24-28. doi: 10.1177/2168479016666587
Damle, N., Shah, S., Nagraj, P., Tabrizi, P., Rodriguez, G., & Bhambri, R. (2016). FDA’s Expedited Programs and Their Impact on the Availability of New Therapies. Therapeutic Innovation & Regulatory Science, 51(1), 24-28. doi: 10.1177/2168479016666587

find the cost of your paper

JOURNAL ARTICLE REVIEW – EMOTIONAL INTELLIGENCE

Each student will select one of the key terms listed  below and conduct a search of our University’s online Library  resources to find 1 recent peer-reviewed article (ATTACHED TO THIS POST) that closely….

9

Using the format outlined on the PICO reference page in the Nursing Reference Center design your own question. (This may be related to something you are familiar with, or something….

management questions

I have 5 questions need to be answers for management class  and the answers from the book  from chapter 1 to 5   the answers should be short  here is….